Clinical Trials Directory

Trials / Terminated

TerminatedNCT00760461

Domperidone in Refractory Gastroparesis

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
44 (actual)
Sponsor
Yale University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to prescribe oral domperidone for patients with gastroparesis who have failed or suffered adverse effects from standard medical therapy.

Conditions

Interventions

TypeNameDescription
DRUGDomperidone10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily

Timeline

Start date
2008-10-01
Primary completion
2011-07-01
Completion
2011-07-01
First posted
2008-09-26
Last updated
2017-08-18
Results posted
2017-08-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00760461. Inclusion in this directory is not an endorsement.

Domperidone in Refractory Gastroparesis (NCT00760461) · Clinical Trials Directory